Five Under 5: Top Oncology Videos for the Week of 12/7

Welcome to The Five Under 5, your go-to roundup of the top 5 videos of the week.

These short videos are designed for busy oncologists to view on the go, and feature expert insights on breaking news, regulatory updates, practice-changing data shared at medical meetings, and other key topics in the realm of oncology.

Here’s what you may have missed:

Efficacy of an All-Oral, Revumenib-Containing Regimen in AML: Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath

Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, of The University of Texas MD Anderson Cancer Center, discussed data from the phase 2 SAVE trial (NCT05360160) examining revumenib (Revuforj) plus decitabine, cedazuridine, and venetoclax (Venclexta) in patients with newly diagnosed acute myeloid leukemia (AML). The findings, which were shared during the 2025 ASH Annual Meeting, revealed an objective response rate (ORR) of 86% with the regimen (n = 21), which Jen noted was high. This included a complete remission (CR)/CR with partial hematologic recovery (CR/CRh) rate of 81% and a CR with incomplete platelet count recovery (CRp) rate of 5%. Moreover, the CR and CRh rates were 76% and 5%, respectively. The median duration of response (DOR) was not reached (NR) at a median follow-up of 9 months, with a 12-month DOR rate of 70% (95% CI, 46%-100%). Regarding safety, myelosuppression and infections were common.

Epcoritamab Plus Lenalidomide and Rituximab in Follicular Lymphoma: Lori A. Leslie, MD

Lori A. Leslie, MD, of John Theurer Cancer Center at Hackensack Meridian Health and Hackensack Meridian School of Medicine, reported 3-year data from arms 6 and 7 of the phase 1b/2 EPCORE NHL-2 trial (NCT04663347) evaluating epcoritamab-bysp (Epkinly) plus rituximab (Rituxan) and lenalidomide (Revlimid; R2) and epcoritamab maintenance in patients with previously untreated follicular lymphoma. In arm 6, epcoritamab plus R2 (n = 41) induced an ORR of 95%, which comprised a CR rate of 88% and a partial response (PR) rate of 7%. Of those who completed treatment in CR (n = 21), 95% maintained response, and the median duration of CR was not reached (NR). The median time to next treatment was also NR. Moreover, approximately 95% (95% CI, 83%-100%) of patients had not received a new anti-lymphoma treatment at 33 months. Serious infections occurred in 32% of patients, neutropenia rates were highest in the first 24 weeks, and cytokine release syndrome (CRS) cases were all grade 1 or 2.

Efficacy of Anitocabtagene Autoleucel in R/R Multiple Myeloma: Krina K. Patel, MD, MSc

Krina K. Patel, MD, MSc, of The University of Texas MD Anderson Cancer Center, shared findings from the phase 2 iMMagine-1 trial (NCT05396885) of anitocabtagene autoleucel in patients with relapsed/refractory multiple myeloma, which were shared during the 2025 ASH Annual Meeting. The CAR T-cell therapy (n = 117) elicited an ORR of 96%, which included a very good partial response or better rate of 88% and stringent CR (sCR)/CR rate of 74% in this population. The median time to first response was 1.0 months (IQR, 1.0-1.9), the median time to best response was 4.8 months (IQR, 2.1-9.0), and the time to sCR/CR was 3.2 months (IQR, 2.0-9.2). The overall minimal residual disease (MRD) negativity rate (10-5 sensitivity level) was 95%, with a median time to MRD negativity of 1.0 month (range, 0.9-6.4), and MRD negativity sustained for at least 6 months for 83% of patients. At a 10-6 sensitivity level, the overall MRD negativity rate was 78%. The 24-month progression-free survival rate and overall survival rates were 61.7% (95% CI, 48.0%-72.8%) and 83.0% (95% CI, 70.7%-90.5%), respectively. The toxicity profile was noted to be predictable and manageable.

Efficacy of Frontline Blinatumomab Plus Ponatinib in Ph+ B-ALL: Hannah Goulart, MD

Hannah Goulart, MD, of The University of Texas MD Anderson Cancer Center, shared long-term data from a phase 2 trial (NCT03263572) investigating first-line blinatumomab (Blincyto) combined with ponatinib (Iclusig) in patients with Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia. The regimen elicited an ORR of 97% with a CR rate of 95%. Ninety-seven percent of patients achieved MRD negativity, with 44% achieving negativity after one cycle of treatment. The median event-free survival and OS have not yet been reached; the 3-year rates were 78% and 89%, respectively. The most common toxicities that were at least grade 3 in severity included increased alanine aminotransferase level, increased lipase, febrile neutropenia, and pneumonia.

Azacitidine Plus Venetoclax and Gilteritinib in FLT3 Wild-Type AML: Sankalp Arora, MD

Sankalp Arora, MD, of The University of Texas MD Anderson Cancer Center, discussed data from a phase 2 study investigating azacitidine (Vidaza) paired with venetoclax (Venclexta) and gilteritinib (Xospata) for use in patients with newly diagnosed, adverse-risk, FLT3 wild-type AML. The regimen led to a composite CR (CRc) rate of 53% in all evaluable patients (n = 15), with CRc rates of 44% and 67% in those with (n = 9) and without (n = 6) TP53 mutations, respectively. Moreover, in those with treated secondary AML (n = 7) and those without (n = 8), the CRc rates with the combination were 29% and 75%, respectively. The median OS and relapse-free survival were NR. With regard to safety, the most frequently experienced grade 3 to 5 non-hematologic toxicities comprised infections, febrile neutropenia, and hypertension.